Japan · Delayed Price · Currency is JPY MedRx Company Description
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan.
The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin.
Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain.
MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
| Country | Japan |
| Founded | 2002 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Yonehiro Matsumura |
Contact Details
Address: 431-7 Nishiyama Higashikagawa, 769-2712 Japan | |
| Phone | 81 8 7923 3071 |
| Website | medrx.co.jp |
Stock Details
| Ticker Symbol | 4586 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3921220004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yonehiro Matsumura | Chief Executive Officer |